PMEF
MRSN

Point72 Middle East FZE’s Mersana Therapeutics MRSN Stock Holding History

Point72 Middle East FZE’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,020
Closed -$59.2K – 855
2023
Q4 		$59.2K Buy
1,020
+46
+5% +$1.85K ﹤0.01% 1260
2023
Q3 		$30.9K Buy
+974
New +$46.3K ﹤0.01% 1283
2023
Q2 		– Sell
-639
Closed -$65.7K – 1891
2023
Q1 		$65.7K Buy
639
+256
+67% +$35.9K ﹤0.01% 1214
2022
Q4 		$56.1K Buy
+383
New +$64.7K ﹤0.01% 1424

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Point72 Middle East FZE's MRSN Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Mersana Therapeutics (MRSN) in Q1 2024, closing a stake of 1,020 shares — an estimated $59.2K sold.

Point72 Middle East FZE first reported a position in MRSN in Q4 2022 and held it in 4 quarters. The position peaked at $65.7K in Q1 2023. 122 funds tracked by Wall St. Rank hold MRSN as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Mersana Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 1,020 Mersana Therapeutics shares in Q1 2024, an estimated $59.2K.
  • Point72 Middle East FZE first reported a position in Mersana Therapeutics in Q4 2022 and held it in 4 quarters.
  • Point72 Middle East FZE's Mersana Therapeutics position peaked at $65.7K in Q1 2023.
  • 122 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.